Citigroup
AKTS

Citigroup’s Aktis Oncology AKTS Stock Holding History

Citigroup’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.2K Buy
+1,019
New +$19.8K ﹤0.01% 4856

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citigroup's AKTS Position: Q1 2026 in Review

Citigroup opened a new position in Aktis Oncology (AKTS) in Q1 2026: 1,019 shares worth $18.2K. The stake represents ﹤0.01% of the portfolio and ranks #4856 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

  • Citigroup held 1,019 shares of Aktis Oncology worth $18.2K as of Q1 2026.
  • Aktis Oncology was a new Citigroup position in Q1 2026.
  • Aktis Oncology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4856 holding.
  • 69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.